The molecular mechanisms responsible for induction or inhibition of apoptosis signal transduction have been intensively investigated during the past few years. Information gained from mechanistic studies and from structural analysis of apoptosis regulatory proteins has provided considerable insight into the pathways that determine whether a cell will live or die. Many of these advances were recently presented at the American
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Nestled amid towering Ponderosa Pines on the shores of scenic Lake Tahoe, 390 scientists gathered between 27 February and 2 March for the American Association for Cancer Research Special Conference on 'Programmed Cell Death Regulation: Basic Mechanisms and Therapeutic Opportunities'. Organizers of the conference were Dr John C Reed (The Burnham Institute, La Jolla, CA, USA) and Dr Junying Yuan (Harvard University, Cambridge, MA, USA). The conference provided greater clarity and understanding regarding many issues in the field of apoptosis, while raising new questions and suggesting new directions. The tenor for the meeting was set by keynote speaker Dr Andrew Wyllie (University of Cambridge, Cambridge, UK) who reviewed 'where we have come from', then asked 'where are we going?'. In rhetorical response, Dr Wyllie raised several questions that are awaiting answers: what is the linkage between cytochrome c release, Bcl-2 family members and Apaf-1? What are the intracellular sites for apoptosis signaling? Are locations other than mitochondria, cytoplasm and nucleus important? Which caspase substrates are critically important for death? Are there alternatives to caspase-mediated death? How does p53 activation feed into apoptosis? In addition to these topics, other issues receiving considerable attention during the conference included the role of intracellular pH changes and the roles of mitochondria and endoplasmic reticulum during apoptosis; the molecular mechanisms of caspase activation; the expression and function of inhibitor of apoptosis proteins (IAPs); the structure of functional domains in apoptosis signaling molecules; the identification of novel apoptosis signaling proteins; and the potential for clinical benefit from apoptosis research.
pH changes during apoptosis
With respect to regulation of intracellular pH during apoptosis, Dr Roberta Gottlieb reported that neutrophils deprived of G-CSF exhibit rapid cytosolic acidification, with cells typically reaching a pH of 6.6. Similar results were seen in Jurkat T leukemic cells undergoing Fas-mediated apoptosis.
1 Acidification was found to be concurrent with phosphatidyl serine (PS) externalization, and it was proposed that the pH sensitivity of the enzyme responsible for flipping PS may account for this commonly observed apoptotic event. Dr Gottlieb also observed that cytoplasmic acidification precedes loss of mitochondrial membrane potential, and can be blocked by expression of Bcl-2. Dr John Reed reported somewhat similar findings, noting that staurosporin can induce a rapid rise in mitochondrial pH which precedes both cytochrome c release and loss of mitochondrial membrane potential. Proapoptotic Bax protein induced cytosolic acidification, and this could be blocked by oligomycin, which inhibits the mitochondrial FoF1-ATPase proton pump.
2 Dr Reed also showed that acidic pH enhances cytochrome c-dependent caspase activation, suggesting how a change in cytosolic pH may further the course of apoptotic execution. In related studies, Dr Donald Nicholson concluded that changes in pH may facilitate the processing and activation of executioner caspases such as caspase-3 (discussed below). Together, these findings indicate that intracellular pH changes are an early event during apoptosis, and may play important roles in driving subsequent biochemical changes associated with the death process.
Role of mitochondria and cytochrome c release
Mitochondria are likely to be important sites for the regulation of cellular pH during apoptosis. However, these organelles also contain other biochemical components which are critical to the death of the cell. It is well established that during apoptosis cytochrome c is released by the mitochondria into the cytoplasm, where it facilitates the initiation of a caspase cascade. [3] [4] [5] Dr Craig Thompson, however, challenged the notion that caspases are the sole mediator of cell death. He noted that caspase inhibitors, while able to block morphologic changes during apoptosis, only serve to delay eventual cell death. He proposed that changes in mitochondrial bioenergetics may ultimately be responsible for the death of the cell. Dr Thompson reported that during apoptosis induced by IL-3 withdrawal, cytoplasmic ATP levels plummet due to impairment of ATP/ADP exchange across the mitochondrial outer membrane. 6 The impairment of this exchange could be prevented by overexpression of Bcl-X L . In cells that do undergo apoptosis, voltage-dependent anion channel (VDAC), located in the outer mitochondrial membrane and a component of the mitochondrial permeability transition pore, is maintained in a closed configuration, preventing ATP/ADP exchange (via the carriers creatine-phosphate/creatine) across the membrane. Bcl-X L was found to maintain VDAC in an open configuration, allowing exchange even in the presence of an apoptotic stimulus. 6 The mechanism of cytochrome c release by mitochondria was addressed by Drs Reed and Stanley Korsmeyer. Previous studies have proposed that during apoptosis mitochondria swell, leading to rupture of the outer mitochondrial membrane and subsequent release of cytochrome c. 7 Dr Reed stated that this is not a likely mechanism for cytochrome c release, since cytochrome c release precedes mitochondrial swelling during staurosporin-induced apoptosis. Moreover, his laboratory has found that Bax-induced cytochrome c release occurs in the absence of swelling. Dr Korsmeyer suggested that oligomerization of proapoptotic proteins such as Bax or Bak in the mitochondrial outer membrane may generate pores with sufficient openings to allow release of cytochrome c. The laboratories of Drs Xiaodong Wang and Junying Yuan have previously shown that stimulation of cell surface death receptors leads to caspase-8-dependent cleavage of Bid protein, which then translocates to the mitochondria and promotes cytochrome c release. 8, 9 Dr Korsmeyer reported that cleaved Bid facilitates the oligomerization of Bak in the outer mitochondrial membrane. Moreover, in artificial lipid membranes, his group found that homotetramers of Bax protein produced sufficient pore sizes to allow the passage of cytochrome c-sized molecules through the membrane. He proposed that oligomers of Bak, Bax, or similar molecules may serve as pores for release of cytochrome c.
Apoptosome structure and function
Following release into the cytosol, cytochrome c is known to interact with Apaf-1 and procaspase-9, forming what is called the apoptosome complex. In the presence of dATP or ATP, apoptosome formation promotes the processing and activation of procaspase-9, initiating a caspase cascade. [3] [4] [5] Several speakers addressed the nature of the apoptosome complex. Chunying Du representing the laboratory of Xiaodong Wang reported the purification and cloning a previously unknown component of the apoptosome, SMAC protein. SMAC, for second mitochondrial activator of caspases, augments procaspase-9 processing by lowering the requirement of the apoptosome for dATP. The SMAC protein was reported to be a 239 amino acid protein unrelated to any known protein. Immunohistochemistry revealed that SMAC is normally localized to the mitochondria, but during apoptosis SMAC, like cytochrome c, is relocalized into the cytosol. Additional insight into apoptosome-mediated caspase-9 activation was provided by Dr Gabriel Nunez. Dr Nunez's group has identified four splice variants of Apaf-1, distinguished by the presence or absence of two small insertions in the Apaf-1 protein sequence. The first insertion is found between the CARD domain and the ATP-binding domain, while the second insertion is located in the C-terminal WD-40 repeat region. The major form of Apaf-1 expressed in cells is the form containing both insertions. Also, the presence of the second insertion is necessary for the ability of Apaf-1 to oligomerize, and to bind cytochrome c and caspase-9.
In the nematode C. elegans, it is well established that the Bcl-2 homolog CED-9 blocks apoptosis by binding to the Apaf-1 homolog CED-4, preventing processing/activation of the caspase protease CED-3.
10,11 However, several investi- [12] [13] [14] According to Dr Nunez, mutants of CED-9 which bind EGL-1, but fail to release CED-4, abrogate downstream activation of CED-3 protease, indicating that CED-4 release is necessary for the protease activation. Additional insights into apoptosome function will likely come from Drosophila; Drs John Abrams and Hermann Steller reported on the discovery of a Drosophila Apaf-1 homolog termed DARK or HAC-1.
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Other subcellular sites of apoptosis signal transduction
While mitochondria, cytoplasm, and nucleus clearly are important locations for apoptosis signal transduction, increased attention is being paid to other subcellular sites. In particular, emerging evidence suggests important roles for proteins associated with the endoplasmic reticulum. Dr Gordon Shore discussed the cloning of a novel protein, BAP31, isolated in a screen for Bcl-2 binding proteins. 16 BAP31 is localized exclusively in the endoplasmic reticulum, with an N-terminus facing the lumen, three transmembrane domains, and a C-terminal death effector domain (DED). In addition to its ability to bind Bcl-2, BAP31 also binds caspase-8. Caspase-8 can cleave BAP31, and the cleavage product is potently proapoptotic. In contrast, overexpression of a noncleavable BAP31 mutant acts to inhibit apoptosis. The normal function of BAP31 is unknown. Dr Junying Yuan, provided more food for thought by reporting that caspase-12 is localized to the endoplasmic reticulum. In cortical neurons, Dr Yuan's group has shown that caspase-12 is required for efficient apoptosis induction by amyloid ␤-protein.
Molecular mechanisms of caspase activation
Another subject that received considerable attention was the molecular mechanism of processing and activation of executioner caspases such as caspase-3 and caspase-7. Dr Donald Nicholson noted that recombinant procaspases typically undergo autoprocessing when they are produced in the acidic environment of bacteria cytosol. He proposed that enzymes such as caspase-3 are normally maintained in zymogen form through a 'safety catch' mechanism, and that this safety catch can be released by a drop in pH. In defining the 'safety catch' Dr Nicholson pointed to a sequence of three consecutive aspartate residues located just beyond the processing site between the large and small subunits of caspase-3. Dr Nicholson indicated that mutational and crystallographic analyses suggest that these aspartate residues fold back and form charge-charge interactions with other amino acids in the caspase-3 sequence. In folding back, this sequence serves as a 'safety catch' by blocking access to the normal processing site. However, when cellular pH is lowered, these chargecharge interactions are disrupted, the 'safety catch' is released, and the processing site becomes vulnerable to cleavage by initiator caspases. A slightly different model, termed the 'booby trap' model was proposed by Dr Guy Salvesen. According to Dr Salvesen, the sequence encompassing the processing site and 'safety catch' exists as a vulnerable loop structure. Activation of the proenzyme requires disruption of this loop. In the case of initiator caspases, the loop is displaced by cofactors (ex. apoptosome components), allowing autoprocessing to occur. For executioner caspases the loop is directly cleaved by upstream proteases, releasing the autoinhibition caused by this structure. In related studies, Dr Junying Yuan showed that not all caspase activation occurs as a result of autocleavage or cleavage by an upstream caspase. She demonstrated that procaspase-12 is subject to processing by the noncaspase, m-calpain. In whole cells, E64d, an inhibitor of m-calpain, blocked cleavage/activation of caspase-12 during amyloid ␤-protein-induced apoptosis.
IAP proteins
Another mechanism regulating the activation and activities of caspases involves the binding and inhibition of these proteases by members of the IAP protein family. 17 IAP proteins are distinguished by the presence of one or more copies of a 70 amino acid motif termed the BIR domain. One of the more intriguing members of the IAP family is the single BIR domaincontaining protein survivin. 18 Survivin is rarely expressed in normal cells and tissues, but has been found to be overexpressed in a large percentage of hematopoietic and solid malignancies. 19 Moreover, survivin is the only member of the IAP family that has been shown to be expressed in a cell cycle-dependent manner; survivin is expressed most prominently during M phase. 20 Dr Dario Altieri reported that survivin, unlike other IAPs, contains a consensus site for phosphorylation by p34 cdc2 kinase. Indeed, threonine, 34 was found to be phosphorylated by the p34 cdc2 /cyclin B1 complex. Importantly, Dr Altieri showed that mutation of threonine 34 to alanine abolished the ability of survivin to bind to caspase-9 and abrogated the antiapoptotic function of survivin.
In contrast to survivin, expression of the IAP protein XIAP 21, 22 is not modulated throughout the cell cycle. Previous studies have shown that XIAP is ubiquitously expressed and is a potent inhibitor of caspases-3, -7 and -9. 21, 23, 24 Despite a lack of transcriptional regulation, Dr Robert Korneluk provided evidence that XIAP protein levels can be modulated by cellular stress. Dr Korneluk showed that XIAP mRNA contains an IRES (Internal Ribosome Entry Site) sequence element, and that this IRES element provides translational control of XIAP production during times of cell stress. 25 The dissection of functional domains in the XIAP protein was reported by Dr Stephen Fesik. Previously, Dr Reed's group had found that the second of XIAPs three BIR domains, together with sequences flanking the BIR2 domain, was sufficient to inhibit caspases-3 and -7. 26 Dr Fesik reported, however, that mutation of a variety of charged and hydrophobic amino acids in the BIR2 domain did not affect the ability of XIAP to inhibit caspases. 27 Rather, mutation of a DISD sequence (to DISA) immediately preceding the BIR2 domain resulted in loss of XIAP activity. Dr Fesik reasoned that the DSID site, which resembles a caspase-3 and -7 consensus cleavage site, probably binds to the active site of the caspase, and allows docking of the remainder of the BIR2 domain elsewhere on the molecule.
Structural analysis of apoptosis regulatory proteins
Further clues about the function of apoptosis regulatory molecules such as XIAP have come from NMR and crystallography studies. Dr Fesik provided an overview of proteins and domain modules whose structures have been determined. Included in this list are death receptors, caspases, Bcl-2 family members, BH3 domains, BIR domains, death domains (DD), death effector domains (DED), and caspase recruitment domains (CARD). Interestingly, the DD, DED and CARD domains, which are commonly found in adaptor or transducer molecules in caspase signaling pathways, have similar physical structures. However, despite similarities in structure, DD, DED and CARD domains utilize different amino acids and mechanisms to facilitate protein-protein interactions. Dr Fesik pointed out that interactions between DD domains are largely dependent on charged amino acids, while interactions of DED domains with other proteins are dependent on two hydrophobic patches on the surface of the DED motif. The CARD domain is primarily alpha helical, with one positively charged face and one negatively charged face. In the interaction of caspase-9 with Apaf-1, negative charges from the caspase-9 CARD domain interact with corresponding positive charges in the CARD domain of Apaf-1.
Novel apoptosis regulatory proteins and novel functions for known proteins
An understanding of the structure and function of various apoptosis domain modules will become increasingly important as evidenced by the cloning of several new proteins containing various combinations of different domains. Dr Reed reported the cloning of BAR (Bifunctional Apoptosis Regulator), as a molecule that can inhibit Bax-induced apoptosis in yeast. Like the BAP31 protein described by Dr Shore, BAR was found capable of binding both Bcl-2 and caspase-8. BAR consists of an N-terminal ring finger, followed by a Bcl-2 binding domain, followed by a DED domain, followed by a C-terminal membrane anchoring domain. Preliminary results from Dr Reed's group suggest that BAR may be upregulated in a large percentage of prostate cancers. Dr Adi Kimchi described the isolation of a proapoptotic molecule called DAP kinase. 28 DAP kinase is a serine/threonine kinase that is regulated by calmodulin binding. In addition to a calmodulin binding domain, DAP kinase also contains a DD domain and ankyrin repeats. A major substrate of DAP kinase appears to be myosin light chain, and phosphorylation of this substrate by DAP kinase may account for some forms of membrane blebbing that occur during apoptosis. Dr Kimchi added that regulation of DAP kinase gene expression via promoter methylation may lead to downregulation of the protein in a significant percentage of breast and colon cancers. 29 Dr Vishva Dixit reported the cloning of a novel CARD domaincontaining protein, termed ICEBERG. ICEBERG appears to act as a decoy adaptor molecule, by binding to caspase-1 and displacing the adaptor RIP2. Normally, RIP2 binds to caspase-1 following stimulation of cells with LPS, promoting the activation of caspase-1 and leading to production of IL-1␤. ICE-BERG can abrogate this process by displacing RIP2 from caspase-1. Dr Dixit proposed that ICEBERG, whose expression is induced by LPS, serves as a 'slow brake' to stem the production of IL-1␤ during inflammation. Dr Tak Mak reported the cloning of a novel p53 kinase, termed p53 bk. This protein was also isolated by Dr Jurg Tschopp as a molecule capable of binding to FAS. Dr Tschopp referred to this protein as FIST, for Fas Interacting Serine/Threonine kinase. It was pointed out by Dr Mak that many breast cancer cell lines have high levels of p53 bk/FIST, and that homozygous inactivation of the p53 bk/FIST gene rendered cells more sensitive to apoptosis. Finally, Dr Korneluk described the cloning of the XIAP binding partner XAF1, a protein consisting of seven zinc finger domains. XAF1 inhibits the ability of XIAP to bind caspase-3 and suppress apoptosis. According to Dr Korneluk, XAF1 is ubiquitously expressed in normal cells, only rarely expressed in cancer cell lines, and exhibits loss of heterozygosity in breast and ovarian cancer specimens.
In attempting to characterize a protein as either pro-or antiapoptotic, it is tempting to do so based on the presence of specific domains in the molecule. However, Dr J Marie Hardwick warned that it is important to keep an open mind. Dr Hardwick has been studying apoptosis of CNS neurons following infection with Sindbis virus. Using in vivo models focusing on hippocampal neurons, she was startled to find that, contrary to dogma, Bax inhibited, while Bcl-X L augmented, viral-induced apoptosis. 30 She also noted that the pro-or antiapoptotic nature of a molecule may depend on the cell type and death stimulus examined. Moreover, she reminded that several antiapoptotic proteins, including Bcl-2 and Bcl-X L , are converted to proapoptotic forms following cleavage by caspase proteases. [31] [32] [33] [34] Thus, there appears to be plasticity of function, at least in the Bcl-2 protein family.
Therapeutic opportunities
Lastly, this conference also provided signs of hope that novel anti-cancer strategies would soon be forthcoming. Perhaps this was best depicted by Dr Avi Ashkenazi and his overview of recent studies with TRAIL ligand. TRAIL is a member of the TNF family of ligands and binds to the cell surface death receptors DR4 and DR5. 35 Binding causes receptor trimerization and induction of apoptosis. Studies from several laboratories have shown that a variety of hematopoietic and solid tumor cell lines are highly sensitive to apoptosis induction by TRAIL. By contrast, most normal cells, although they also express DR4/5, appear to be resistant to TRAIL. This may be due to the expression of dominant-negative-acting decoy receptors (DcR1 and DcR2) on the surface of normal cells. 35 As recently described, 36, 37 Dr Ashkenazi reiterated that dramatic responses to TRAIL have been seen in tumor xenografts in mice, particularly when TRAIL is used in combination with chemotherapy. TRAIL caused delays in tumor progression, as well as shrinkage of established tumors. Notable responses were seen using colon, lung, glioma, and breast cancer cells. Dr Ashkenazi also noted that further studies have shown that high doses of TRAIL are tolerated by monkeys, with no observable cytotoxic effects. 37 By contrast, TNF, when used at a 3000-fold lower dose produced substantial cytotoxicity. While the picture appears rosy for the application of TRAIL in cancer therapy, some concern was raised that we don't yet know which normal human cell types may be affected by TRAIL. The fact that TRAIL receptors are somewhat ubiquitously expressed suggests that TRAIL must have a normal biological function, and that sensitive cells may be adversely affected if TRAIL is administered systemically. Thus, determination as to whether TRAIL can approach a 'magic bullet' status will clearly require additional investigation. As judged by the posters and presentations at this conference, it appears likely that TRAIL, as well as other novel therapeutic strategies, will be vigorously pursued in the near future.
